Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.205 -0.015 (-1.23%)
Streaming Delayed Price Updated: 12:36 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 499,711
Open 1.220
Bid (Size) 1.200 (85)
Ask (Size) 1.210 (21)
Prev. Close 1.220
Today's Range 1.200 - 1.270
52wk Range 0.6611 - 5.920
Shares Outstanding 98,384,456
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
4 Analysts Assess Fate Therapeutics: What You Need To Know
Via Benzinga
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-32.7%
-32.7%
1 Month
-3.6%
-3.6%
3 Month
-21.2%
-21.2%
6 Month
-46.9%
-46.9%
1 Year
-69.2%
-69.2%

More News

Read More
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
Gapping stocks in Monday's session
Via Chartmill
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic
Via Stocktwits
Exposures Product Safety
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Wednesday?
Via Chartmill
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics to Present at Upcoming Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Announces Leadership Transition
From Fate Therapeutics, Inc.
Via GlobeNewswire
Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Fate Therapeutics to Present at Upcoming December Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Fate Therapeutics, Inc. - Common Stock publicly traded?
Yes, Fate Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Fate Therapeutics, Inc. - Common Stock trade on?
Fate Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Fate Therapeutics, Inc. - Common Stock?
The ticker symbol for Fate Therapeutics, Inc. - Common Stock is FATE on the Nasdaq Stock Market
What is the current price of Fate Therapeutics, Inc. - Common Stock?
The current price of Fate Therapeutics, Inc. - Common Stock is 1.205
When was Fate Therapeutics, Inc. - Common Stock last traded?
The last trade of Fate Therapeutics, Inc. - Common Stock was at 05/20/25 12:36 PM ET
What is the market capitalization of Fate Therapeutics, Inc. - Common Stock?
The market capitalization of Fate Therapeutics, Inc. - Common Stock is 118.55M
How many shares of Fate Therapeutics, Inc. - Common Stock are outstanding?
Fate Therapeutics, Inc. - Common Stock has 119M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.